Compare PEG & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEG | KVUE |
|---|---|---|
| Founded | 1903 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Specialty Chemicals |
| Sector | Utilities | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 34.2B |
| IPO Year | 1994 | 2023 |
| Metric | PEG | KVUE |
|---|---|---|
| Price | $70.09 | $17.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $92.79 | $19.45 |
| AVG Volume (30 Days) | 2.3M | ★ 24.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | 3.37% | ★ 4.82% |
| EPS Growth | 19.21 | ★ 40.74 |
| EPS | ★ 2.15 | 0.48 |
| Revenue | $12,168,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $4.89 | $4.85 |
| Revenue Next Year | $4.16 | $2.63 |
| P/E Ratio | ★ $33.01 | $37.48 |
| Revenue Growth | ★ 18.25 | N/A |
| 52 Week Low | $70.05 | $14.02 |
| 52 Week High | $87.63 | $20.13 |
| Indicator | PEG | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 28.68 | 36.86 |
| Support Level | N/A | $17.86 |
| Resistance Level | $81.50 | $19.15 |
| Average True Range (ATR) | 1.00 | 0.31 |
| MACD | -0.16 | -0.07 |
| Stochastic Oscillator | 3.80 | 20.19 |
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plants and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system under a contract extension through 2030. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.